The present invention relates to novel glucocorticoid receptor antagonists for producing a drug for the prophylaxis and therapy of glucocorticoid-mediated hypogonadism, sexual dysfunctions and/or infertility.
For purposes of the present invention, by “glucocorticoid receptor antagonists” are meant drugs capable of competitively inhibiting the effect of glucocorticoids as a result of better and more selective binding to glucocorticoid receptors
The compounds according to the invention or used according to the invention are characterized in that they are significantly more dissociated, namely they bind well to the glucocorticoid receptor and act on the progesterone receptor only to aminor degree compared to 11&bgr;-(4-dimethylamino)phenyl-17&bgr;-hydroxy-17&agr;-propyn-1-yl-estra-4,9-dien-3-one (RU 38486), a substance of very high activity but low selectivity.
本发明涉及一种新型糖皮质激素受体拮抗剂,用于制备预防和治疗糖皮质激素介导的性腺功能减退、性功能障碍和/或不育症的药物。根据本发明的目的,“糖皮质激素受体拮抗剂”指的是具有更好和更选择性结合糖皮质激素受体的药物,能够竞争性地抑制糖皮质激素的作用。根据本发明的化合物或使用本发明的化合物的特点在于它们显著地更易分离,即与糖皮质激素受体结合良好,对孕激素受体的作用仅比11β-(4-
二甲氨基)苯基-17β-羟基-17α-炔-1-基-麦司卡林(RU 38486)略微作用,后者是一种非常高活性但选择性较低的物质。